BR112012014299A2 - composto de antivírus heterocíclicos - Google Patents

composto de antivírus heterocíclicos

Info

Publication number
BR112012014299A2
BR112012014299A2 BR112012014299A BR112012014299A BR112012014299A2 BR 112012014299 A2 BR112012014299 A2 BR 112012014299A2 BR 112012014299 A BR112012014299 A BR 112012014299A BR 112012014299 A BR112012014299 A BR 112012014299A BR 112012014299 A2 BR112012014299 A2 BR 112012014299A2
Authority
BR
Brazil
Prior art keywords
antivirus
heterocyclic
compound
disclosed
compounds
Prior art date
Application number
BR112012014299A
Other languages
English (en)
Inventor
Francisco Xavier Talamas
Leanna Renee Staben
Ryan Craig Schoenfeld
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012014299A2 publication Critical patent/BR112012014299A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

compostos e antivírus heterocíclicos expõem-se compostos que são dotados da fórmula i em que r^ 1^, r^ 2^, r^ 3^, r^ 4^, r^ 5^, r^ a^, r^ b^, r^ c^, r^ d^ e n são tais como definidos neste contexto os quais são inibidores de polimerase de vírus ns5b de hepatite c. expõem-se igualmente composições e métodos para o tratamento de uma infecção por hcv e inibição de replicação de hcv.
BR112012014299A 2009-12-14 2010-12-13 composto de antivírus heterocíclicos BR112012014299A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28613609P 2009-12-14 2009-12-14
PCT/EP2010/069442 WO2011073114A1 (en) 2009-12-14 2010-12-13 Heterocyclic antiviral compounds

Publications (1)

Publication Number Publication Date
BR112012014299A2 true BR112012014299A2 (pt) 2016-07-05

Family

ID=43446588

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012014299A BR112012014299A2 (pt) 2009-12-14 2010-12-13 composto de antivírus heterocíclicos

Country Status (12)

Country Link
US (1) US20110123490A1 (pt)
EP (1) EP2513092A1 (pt)
JP (1) JP2013513584A (pt)
KR (1) KR20120104343A (pt)
CN (1) CN102652134A (pt)
AR (1) AR079440A1 (pt)
BR (1) BR112012014299A2 (pt)
CA (1) CA2780526A1 (pt)
MX (1) MX2012006513A (pt)
RU (1) RU2012129657A (pt)
TW (1) TW201144298A (pt)
WO (1) WO2011073114A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178547B2 (en) * 2008-12-22 2012-05-15 Roche Palo Alto Llc Heterocyclic antiviral compounds
AU2010330048B9 (en) 2009-12-11 2015-02-19 Autifony Therapeutics Limited Imidazolidinedione derivatives
CA2817205C (en) 2010-12-06 2020-04-07 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
US9193704B2 (en) 2011-06-07 2015-11-24 Autifony Therapeutics Limited Hydantoin derivatives as KV3 inhibitors
ES2576628T3 (es) * 2011-12-06 2016-07-08 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
BR112014028718A2 (pt) 2012-05-22 2017-06-27 Autifony Therapeutics Ltd derivados de hidantoína como inibidores de kv3
US9422252B2 (en) 2012-05-22 2016-08-23 Autifony Therapeutics Limited Triazoles as Kv3 inhibitors
CN106065009B (zh) * 2014-06-28 2019-03-01 广东东阳光药业有限公司 作为丙型肝炎抑制剂的化合物及其在药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2014147354A (ru) * 2007-09-17 2015-07-10 Эббви Бахамаз Лтд. Пиримидины, которые могут быть использованы в качестве противоинфекционных средств, и их применения
CN102746239B (zh) * 2007-09-17 2016-02-10 艾伯维巴哈马有限公司 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物
CN102448952B (zh) * 2009-03-25 2014-10-29 Abbvie公司 抗病毒化合物和其用途

Also Published As

Publication number Publication date
RU2012129657A (ru) 2014-01-27
WO2011073114A1 (en) 2011-06-23
TW201144298A (en) 2011-12-16
MX2012006513A (es) 2012-07-17
JP2013513584A (ja) 2013-04-22
EP2513092A1 (en) 2012-10-24
KR20120104343A (ko) 2012-09-20
AR079440A1 (es) 2012-01-25
CA2780526A1 (en) 2011-06-23
CN102652134A (zh) 2012-08-29
US20110123490A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
BR112012015951A2 (pt) 4 azido-nucleosídeos como compostos anti-hcv
BR112012014299A2 (pt) composto de antivírus heterocíclicos
MX2012003170A (es) Compuestos heterociclicos antivirales.
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
MX2010004623A (es) Compuestos heterociclicos antiviricos.
CO6440581A2 (es) Inhibidores del virus de la hepatitis c
CO6382110A2 (es) Compuestos para el tratamiento de la hepatitis c.
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
BR112016004919A2 (pt) Inibidores de polimerase de hcv
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
UA108351C2 (uk) Інгібітори реплікації вірусу гепатиту c
NO341663B1 (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
EA201270622A1 (ru) Ингибиторы вируса гепатита с
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
CY1118567T1 (el) Αναστολεις του ιου της ηπατιτιδας c
BR112012008533A2 (pt) combinações de inibidores do vírus de hepatite c
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
CL2011001364A1 (es) Compuestos derivados de nucleotidos de uracil ciclopropilicos, inhibidores de la polimerasa del virus de la hepatitis c; composiciones farmaceuticas; y uso del compuesto para el tratamiento de hepatitis c (hcv).
ECSP11011513A (es) Compuestos heterocíclicos antivirales
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
EA201391717A1 (ru) Ингибиторы вируса гепатита с

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]